Robert Rotche, MD
Hematology & Oncology · Christiansburg, VANPI 1417924101
Payments from drug & device makers
Across 88 payments — averaging $90.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AstraZeneca$3K
- Incyte Corporation$570
- Pfizer$169
- Novartis$147
- E.r. Squibb & Sons, L.L.C.$98
- plus $1000 from 33 others
What the payments were for
- Consulting fees$5,53070%
- Speaking & faculty fees$5006%
- Travel & lodging$1662%
- Food & beverage$1,60220%
- Education$1352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $3,049 |
| AstraZeneca | 5 | $2,899 |
| Incyte Corporation | 4 | $570 |
| Pfizer | 7 | $169 |
| Novartis | 7 | $147 |
| E.r. Squibb & Sons, L.L.C. | 5 | $98 |
| Tactile Systems Technology Inc | 3 | $90 |
| Gilead(2 entities) | 4 | $70 |
| Seagen Inc. | 4 | $61 |
| AbbVie | 2 | $47 |
| Amgen | 3 | $44 |
| Sanofi | 2 | $41 |
| Beigene USA, Inc. | 2 | $36 |
| GSK | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Bristol Myers Squibb | 2 | $35 |
| Genentech USA, Inc. | 2 | $33 |
| Stemline Therapeutics Inc. | 2 | $31 |
| Exelixis Inc. | 1 | $29 |
| Myovant Sciences Inc. | 1 | $28 |
| Lilly USA, LLC | 2 | $28 |
| Bayer | 2 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $25 |
| EMD Serono, Inc. | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Mirati Therapeutics, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,933 in reported general payments places this provider in the 60th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 36 | $631,901 |
| BrukinsaZanubrutinib | 21 | $326,033 |
| Lenalidomide | 19 | $311,756 |
| NubeqaDarolutamide | 30 | $240,143 |
| XtandiEnzalutamide | 16 | $226,832 |
| EliquisApixaban | 23 | $13,534 |
| Imatinib Mesylate | 12 | $2,721 |
| Letrozole | 101 | $1,644 |
| Oxycodone Hcl | 51 | $960 |
| Hydroxyurea | 32 | $792 |
| Exemestane | 13 | $689 |
| Gabapentin | 15 | $547 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $406 |
| Ondansetron Hcl | 36 | $403 |
| Dexamethasone | 21 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $570 | $631,90136 claims |
| Beigene USA, Inc.Brukinsa | $36 | $326,03321 claims |
| BayerNubeqa | $27 | $240,14330 claims |
| Astellas Pharma US IncXtandi | $15 | $226,83216 claims |
| PfizerEliquis | $169 | $13,53423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Christiansburg
- Jerome GoldschmidtChristiansburg$6.5M
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- William IrvinMidlothian$4.3M
- Lakshminarayanan NandagopalFredericksburg$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.